KKR and Hologic team up to create medical tech platform focused on lung cancer diagnostics
Private-equity firm KKR & Co. Inc. (KKR), Hologic Inc. (HOLX) are teaming up to create a new platform aimed at accelerating innovation in medical technology with an initial focus on lung cancer, the leading cause of cancer deaths. The platform will be named Maverix Medical and will be managed by Ajax Health under the stewardship of Duke Rohlen. KKR and Ajax will contribute the portfolio company Serpex Medical to the platform, as it's already working on technology to target lung tissue for biopsy or delivery of therapy. KKR's stock has gained 61% in the year to date, while the S&P 500 has gained 18.5%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-30-23 0616ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom